Positive Phase III results for Shanghai’s Junshi Biosciences (HKEX: 1877) will lift the company’s prospects in the competitive market for lung cancer therapies.
Results from a prespecified interim analysis of the NEOTORCH trial show the primary endpoint of event-free survival (EFS) has been met.
Junshi is running the trial to test its checkpoint blocker toripalimab, in combination with chemo, as a perioperative treatment for certain people with non-small cell lung cancer (NSCLC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze